Navigation Links
China to make cheaper version of GSK’s flu dru

GlaxoSmithKline signed an agreement with Simcere Pharmaceutical Group of Nanjing, China for it to manufacture and sell a cheaper version of its flu drug Relenza in poor countries//.

The Chinese company can manufacture and sell zanamivir in China, Indonesia, Thailand, Vietnam and all least-developed countries, under the terms of licensing agreement.

"GSK is doing everything we can to prepare for a global influenza pandemic, including expanding production of Relenza and developing a pandemic vaccine," said David Stout, GSK's president of pharmaceutical operations. "This agreement with Simcere is intended to expand available supplies of zanamivir in areas of the world that may be on the front line of a possible influenza pandemic," Stout added.

Relenza is an inhaled drug and is meant to be a first-line defense in the event of an influenza pandemic set off by bird flu. It is approved in many countries around the world.
GYT
'"/>




Page: 1

Related medicine news :

1. China tells officials not to hide SARS damage
2. China reports declining number of SARS Cases
3. China says patient may have SARS
4. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
5. Adverse Effects Associated with Unauthorised Hepatitis A Vaccine in China
6. Pig Bacterium (Streptococcus suis) Kills 24 In China
7. Watch Out! Pollution hazard from E-waste recycling in India & China
8. French Fries In Cancer Controversy In China
9. China To Distribute Free Condoms To Combat AIDS/HIV
10. HIV Cases Steadily Increasing In China With The Toll Over 1.26 Lakh
11. India And China Discuss Import Of Encephalitis Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... to catalyze conversations in support of bold systems change models helping to achieve ... an event on September 21, 2017, “We the Future: Accelerating Sustainable Development Solutions” ...
(Date:8/17/2017)... ... August 17, 2017 , ... SeQuel Response announced today that for ... among the fastest-growing private companies in the U.S., putting it in the top 10 ... applied to the Inc. 5000 over the years, only a fraction have ...
(Date:8/17/2017)... ... 2017 , ... Dr. Charles W. Grimsley’s new book ... 9781498497626; $7.99, eBook, 9781498497633) focuses on the treatment of veterans diagnosed with posttraumatic ... through a progressive journey toward healing. This book will help readers learn to ...
(Date:8/17/2017)... ... August 17, 2017 , ... Momkus McCluskey Roberts LLC recently ... is a member of the firm’s Commercial Litigation and Employment Law groups. , Ms. ... of knowledge in matters of employment litigation, commercial litigation and business disputes. Her experience ...
(Date:8/17/2017)... ... August 17, 2017 , ... A recent report indicates that circa 79 percent ... cited deficiencies in data integrity. The FDA outlines their expectations for quality critical instrumentation ... as part of the Beckman Coulter Life Sciences Virtual Trade Show Virtual ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Mich., Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), ... the quarter ended June 30, 2017.  All comparisons, unless otherwise ... Second Quarter 2017 Highlights ... to $1,089 million, an increase of 3.5% ... Gross margin of 7.5% versus 7.6% ...
(Date:8/4/2017)... 4, 2017 The search for test results ... physician/patient consult has long been the goal of healthcare ... focus of the largest meeting of lab professionals and ... market research firm Kalorama Information.  The firm said scores ... or related supplies and software were at the American ...
Breaking Medicine Technology: